Abstract:Parkinson's disease (PD) is characterized pathologically by the selective loss of substantia nigra (SN) dopaminergic (DAergic) neurons. Recent evidence has suggested a role of LRRK2, linked to the most frequent familial PD, in regulating synaptic vesicle (SV) trafficking. However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear. Here we show that the most common PD mutationLRRK2 G2019Simpairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity. A similar endocytic defect, however, was not observed in LRRK2 mutant neurons from the neocortex (hereafter, cortical neurons) or the hippocampus, suggesting a brain region-specific vulnerability to the G2019S mutation. Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion ofSYNJ1(PARK20), a gene that is associated with recessive Parkinsonism. CombiningSYNJ1+/−andLRRK2 G2019Sdoes not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice. Interestingly, we show that LRRK2 directly phosphorylates synaptojanin1in vitro, resulting in the disruption of endophilin-synaptojanin1 interaction required for SV endocytosis. Our work suggests a merge ofLRRK2andSYNJ1pathogenic pathways in deregulating SV trafficking in MB neurons as an underlying molecular mechanism of early PD pathogenesis.SIGNIFICANCE STATEMENTUnderstanding midbrain dopaminergic (DAergic) neuron-selective vulnerability in PD is essential for the development of targeted therapeutics. We report, for the first time, a nerve terminal impairment in SV trafficking selectively in MB neurons but not cortical neurons caused by two PARK genes:LRRK2(PARK8) andSYNJ1(PARK20). We demonstrate that the enhanced kinase activity resulting from the most frequentG2019Smutation inLRRK2is the key to this impairment. We provide evidence suggesting thatLRRK2 G2019SandSYNJ1loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.

LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons

“LRRK2: Autophagy and Lysosomal Activity”

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics

Kinase Activity of Mutant LRRK2 Mediates Neuronal Toxicity

LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation

Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia

Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson's Disease?

LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner

Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons

Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival

LRRK2 G2019S Mutation Inhibits Degradation of Α-Synuclein in an in Vitro Model of Parkinson’s Disease

Parkinson's-linked LRRK2-G2019S derails AMPAR trafficking, mobility, and composition in striatum with cell-type and subunit specificity

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

Leucine-Rich Repeat Kinases

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons